Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Chao Chen, Ning Wu & Crystal Watson. (2018) Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon. ClinicoEconomics and Outcomes Research 10, pages 723-730.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza & Márcio Machado. (2017) Comparative effectiveness of interferons in relapsing–remitting multiple sclerosis: a meta-analysis of real-world studies. Current Medical Research and Opinion 33:3, pages 579-593.
Read now
Read now
Xuehua Ke, Prakash Navaratnam, Rahul Sasane, Debra F. Eisenberg Lawrence, Howard S. Friedman, Bernard B. Tulsi & Timothy Vollmer. (2016) Determinants of high cost in multiple sclerosis patients: a claims and chart review study. Current Medical Research and Opinion 32:9, pages 1589-1597.
Read now
Read now
Aaron Boster & Michael K Racke. (2009) Pharmacotherapy of multiple sclerosis: the PROOF trial. Expert Opinion on Pharmacotherapy 10:8, pages 1235-1237.
Read now
Read now
Articles from other publishers (19)
Robert W. Baumhefner & Mei Leng. (2022) Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage. Neurology and Therapy 11:3, pages 1399-1408.
Crossref
Crossref
Per Soelberg Sorensen. (2022) Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis. CNS Drugs 36:6, pages 569-589.
Crossref
Crossref
Cristina-Florentina Plesa, Diana Maria Chitimus, Carmen Adella Sirbu, Monica Marilena Țânțu, Minerva Claudia Ghinescu, Daniela Anghel & Florentina Ionita-Radu. (2022) Thrombotic Thrombocytopenic Purpura in Interferon Beta-1a-Treated Patient Diagnosed with Relapsing-Remitting Multiple Sclerosis: A Case Report. Life 12:1, pages 80.
Crossref
Crossref
Stanley L. Cohan, Barry A. Hendin, Anthony T. Reder, Kyle Smoot, Robin Avila, Jason P. Mendoza & Bianca Weinstock-Guttman. (2021) Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs 35:7, pages 743-767.
Crossref
Crossref
Christina HermanrudToni M.M. van CapelMichael AuerVirginija KarrenbauerFlorian DeisenhammerEsther C. de JongAnna Fogdell-Hahn. (2019) Different Interferon Beta Preparations Induce the Same Qualitative Immune Response in Human Skin. Journal of Interferon & Cytokine Research 39:5, pages 302-313.
Crossref
Crossref
Dejan Jakimovski, Channa Kolb, Murali Ramanathan, Robert Zivadinov & Bianca Weinstock-Guttman. (2018) Interferon β for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine 8:11, pages a032003.
Crossref
Crossref
Karthik Govindappa, Jean Sathish, Kevin Park, Jamie Kirkham & Munir Pirmohamed. (2015) Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis. European Journal of Clinical Pharmacology 71:11, pages 1287-1298.
Crossref
Crossref
Axel Petzold, Robert Bowser, Paolo Calabresi, Henrik Zetterberg & Bernard MJ Uitdehaag. (2014) Biomarker time out. Multiple Sclerosis Journal 20:12, pages 1560-1563.
Crossref
Crossref
Jennifer L. Rojko, Mark G. Evans, Shari A. Price, Bora Han, Gary Waine, Mark DeWitte, Jill Haynes, Bruce Freimark, Pauline Martin, James T. Raymond, Winston Evering, Marlon C. Rebelatto, Emanuel Schenck & Christopher Horvath. (2014) Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes. Toxicologic Pathology 42:4, pages 725-764.
Crossref
Crossref
Swaminathan Sethu, Karthik Govindappa, Paul Quinn, Meenu Wadhwa, Richard Stebbings, Mike Boggild, Dean Naisbitt, Ian Kimber, Munir Pirmohamed, Kevin Park & Jean Sathish. (2013) Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement. Clinical Immunology 148:2, pages 177-185.
Crossref
Crossref
Bianca Weinstock-Guttman, Murali Ramanathan & Robert ZivadinovCarlo PozzilliLuca Prosperini. 2013. Personalized Management of Multiple Sclerosis. Personalized Management of Multiple Sclerosis
108
122
.
G Giovannoni, E Southam & E Waubant. (2012) Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Multiple Sclerosis Journal 18:7, pages 932-946.
Crossref
Crossref
Richard A Rudick & Robert A BermelR Philip KinkelAugusto Miravalle. 2011. Addressing Unmet Medical Needs in Relapsing–Remitting Multiple Sclerosis. Addressing Unmet Medical Needs in Relapsing–Remitting Multiple Sclerosis
6
25
.
Per Soelberg Sørensen. 2011. Multiple Sclerosis Therapeutics. Multiple Sclerosis Therapeutics
287
299
.
. 2011. Multiple Sclerosis Therapeutics. Multiple Sclerosis Therapeutics
56
299
.
Volker Limmroth, Norman Putzki & Norman J. Kachuck. (2011) The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Therapeutic Advances in Neurological Disorders 4:5, pages 281-296.
Crossref
Crossref
Brant J. Oliver, Erol Kohli & Lloyd H. Kasper. (2011) Interferon therapy in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis of the comparative trials. Journal of the Neurological Sciences 302:1-2, pages 96-105.
Crossref
Crossref
M. Dieterich & G. F. Hamann. (2009) Bericht vom NeuroUpdate der Med-Update-Reihe in Wiesbaden (13./14.02.09)Report from NeuroUpdate in Wiesbaden (13/14 February 2009). Der Nervenarzt 80:6, pages 720-724.
Crossref
Crossref
Per Soelberg Sorensen. (2008) Review: Neutralizing antibodies against interferon-beta. Therapeutic Advances in Neurological Disorders 1:2, pages 125-141.
Crossref
Crossref